Bristol-Myers Squibb Company (BMY), Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer and Bristol-Myers Squibb are conducting a study titled A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma. The study aims to evaluate the safety and tolerability of combining elranatamab and iberdomide for treating relapsed or refractory multiple myeloma, a challenging form of cancer that resists treatment or returns after improvement. The study tests two drugs: elranatamab, a BCMA-CD3 bispecific antibody, and iberdomide, a cereblon-modulating agent. Elranatamab is administered as an injection under the skin, while iberdomide is taken orally for 21 days in a 28-day cycle. This interventional study is randomized and follows a sequential intervention model with no masking, focusing on treatment as its primary purpose. It is divided into two parts: dose escalation and dose randomization. The study began on February 20, 2024, with an initial submission date of January 10, 2024. The latest update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders. This study could significantly impact the stock performance of Pfizer and Bristol-Myers Squibb by potentially introducing a new treatment option for multiple myeloma, thereby enhancing investor confidence. The competitive landscape in the oncology sector could see shifts depending on the study’s outcomes. The study is currently recruiting, with further details available on the ClinicalTrials portal.

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment

Pfizer Inc and Bristol-Myers Squibb Company have announced an update on their Phase 1B, open-label clinical study evaluating the combination of elranatamab and iberdomide for treating relapsed or refractory multiple myeloma. The study assesses the safety and tolerability of the drug combination, with elranatamab administered via subcutaneous injection and iberdomide taken orally in a 21-day cycle within a 28-day cycle. The trial began on February 20, 2024, with an initial submission on January 10, 2024, and the latest update was submitted on August 12, 2025. The study is currently recruiting and could influence stock performance and the competitive dynamics in the oncology sector.